Abstract
The use of oncolytic herpes simplex virus type 1 (HSV-1) is a promising strategy for cancer treatment. Accumulating evidence indicates that, aside from the extent of replication capability within the tumor, the efficacy of an oncolytic HSV-1 depends on the extent of induction of host antitumor immune responses. Ways to modify the host immune responses toward viral oncolysis include expression of immunostimulatory molecules using oncolytic HSV-1 as a vector and co-administration of reagents that modulate immune reactions. Viral propagation may be enhanced via temporary suppression of innate immune responses. Elucidation of the role of the host immune system in oncolytic HSV-1 therapy is the key to establishing the approach as a useful clinical means for cancer treatment.
Keywords: Herpes simplex virus type 1, oncolytic virus therapy, antitumor immunity, cancer immunotherapy, innate immunity
Current Cancer Drug Targets
Title: Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Volume: 7 Issue: 2
Author(s): Hiroshi Fukuhara and Tomoki Todo
Affiliation:
Keywords: Herpes simplex virus type 1, oncolytic virus therapy, antitumor immunity, cancer immunotherapy, innate immunity
Abstract: The use of oncolytic herpes simplex virus type 1 (HSV-1) is a promising strategy for cancer treatment. Accumulating evidence indicates that, aside from the extent of replication capability within the tumor, the efficacy of an oncolytic HSV-1 depends on the extent of induction of host antitumor immune responses. Ways to modify the host immune responses toward viral oncolysis include expression of immunostimulatory molecules using oncolytic HSV-1 as a vector and co-administration of reagents that modulate immune reactions. Viral propagation may be enhanced via temporary suppression of innate immune responses. Elucidation of the role of the host immune system in oncolytic HSV-1 therapy is the key to establishing the approach as a useful clinical means for cancer treatment.
Export Options
About this article
Cite this article as:
Fukuhara Hiroshi and Todo Tomoki, Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses, Current Cancer Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/156800907780058907
DOI https://dx.doi.org/10.2174/156800907780058907 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target
Current Pharmaceutical Biotechnology DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Nanoparticles in Melanoma
Current Medicinal Chemistry Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Targeted Alpha Therapy with 213Bi
Current Radiopharmaceuticals 2,4-Thiazolidinedione as Precursor to the Synthesis of Compounds with Anti-glioma Activities in C6 and GL261 Cells
Medicinal Chemistry Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?
Current Topics in Medicinal Chemistry Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine